StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) stock

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.92−0.09 (-8.88%)

Close on Nov 17, 2026Market cap $8.70MP/E –Yield –

Cellectar Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Cellectar Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.25M, down 24.4% year over year. For fiscal 2025 it was $11.50M, down 56.0% from the year before. Over ten years it grew 8.3% a year on average. The highest annual figure on record is $27.27M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.50M-56.0%
FY2024Dec 31, 2024$26.14M-4.1%
FY2023Dec 31, 2023$27.27M+49.3%
FY2022Dec 31, 2022$18.27M+3.9%
FY2021Dec 31, 2021$17.59M+73.4%
FY2020Dec 31, 2020$10.14M+12.7%
FY2019Dec 31, 2019$9.00M+31.6%
FY2018Dec 31, 2018$6.84M-27.8%
FY2017Dec 31, 2017$9.47M+99.3%
FY2016Dec 31, 2016$4.75M-7.9%
FY2015Dec 31, 2015$5.16M-13.5%
FY2014Dec 31, 2014$5.96M-13.1%
FY2013Dec 31, 2013$6.86M+33.9%
FY2012Dec 31, 2012$5.12M+42.3%
FY2011Dec 31, 2011$3.60M+20.6%
FY2010Dec 31, 2010$2.98M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.56M+90.7%
Q1 FY2026Mar 31, 2026$3.01M-12.3%
Q4 FY2025Dec 31, 2025$3.16M-49.1%
Q3 FY2025Sep 30, 2025$2.52M-54.1%
Q2 FY2025Jun 30, 2025$2.39M-67.5%
Q1 FY2025Mar 31, 2025$3.43M-51.6%
Q4 FY2024Dec 31, 2024$6.21M-19.8%
Q3 FY2024Sep 30, 2024$5.49M-21.9%
Q2 FY2024Jun 30, 2024$7.35M+19.7%
Q1 FY2024Mar 31, 2024$7.09M+11.5%
Q4 FY2023Dec 31, 2023$7.74M+71.9%
Q3 FY2023Sep 30, 2023$7.03M+35.0%
Q2 FY2023Jun 30, 2023$6.14M+48.0%
Q1 FY2023Mar 31, 2023$6.36M+71.7%
Q4 FY2022Dec 31, 2022$4.50M+2.5%
Q3 FY2022Sep 30, 2022$5.21M+32.3%
Q2 FY2022Jun 30, 2022$4.14M-10.4%
Q1 FY2022Mar 31, 2022$3.70M-20.1%
Q4 FY2021Dec 31, 2021$4.39M+84.8%
Q3 FY2021Sep 30, 2021$3.94M+46.7%
Q2 FY2021Jun 30, 2021$4.63M+87.7%
Q1 FY2021Mar 31, 2021$4.63M+77.1%
Q4 FY2020Dec 31, 2020$2.38M+9.2%
Q3 FY2020Sep 30, 2020$2.68M-0.7%
Q2 FY2020Jun 30, 2020$2.47M+36.2%
Q1 FY2020Mar 31, 2020$2.62M+13.3%
Q4 FY2019Dec 31, 2019$2.17M+109.7%
Q3 FY2019Sep 30, 2019$2.70M+35.5%
Q2 FY2019Jun 30, 2019$1.81M+5.0%
Q1 FY2019Mar 31, 2019$2.31M+8.7%
Q4 FY2018Dec 31, 2018$1.04M-66.6%
Q3 FY2018Sep 30, 2018$2.00M-14.5%
Q2 FY2018Jun 30, 2018$1.72M-20.8%
Q1 FY2018Mar 31, 2018$2.12M+14.4%
Q4 FY2017Dec 31, 2017$3.10M+115.2%
Q3 FY2017Sep 30, 2017$2.33M+78.7%
Q2 FY2017Jun 30, 2017$2.18M–
Q1 FY2017Mar 31, 2017$1.86M–
Q4 FY2016Dec 31, 2016$1.44M–
Q3 FY2016Sep 30, 2016$1.31M–

More Cellectar Biosciences figures

See a number that looks wrong?